Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Non-Hodgkin 18Lymphoma 17Lymphoma, Follicular 15Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 10Lymphoma, Large B-Cell, Diffuse 9Multiple Myeloma 8Leukemia 6Waldenstrom Macroglobulinemia 5Hodgkin Disease 5Neoplasms 4Sezary Syndrome 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Mycosis Fungoides 3Burkitt Lymphoma 3Neoplasms, Plasma Cell 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Brain Neoplasms 2Advanced Solid Tumor 2

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × Bendamustine Hydrochloride × Clear all
NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic

Phase 1 Recruiting
12 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡